PMID- 37254545
OWN - NLM
STAT- MEDLINE
DCOM- 20230904
LR  - 20231002
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 23
IP  - 11
DP  - 2023
TI  - Comprehensive Analysis of Diabetes Mellitus-related Gene Expression and 
      Associated Prognoses in Human Lung Cancer.
PG  - 889-899
LID - 10.2174/1568009623666230529154306 [doi]
AB  - INTRODUCTION: Diabetes mellitus (DM) is a major public health problem worldwide. 
      Cancer is the second most common cause of death in the United States and the 
      leading cause of death in China. There is compelling evidence that individual 
      risk for type 2 diabetes mellitus (T2DM) is strongly influenced by genetic 
      factors. DM and cancer may interact with one another; some kinds of cancer 
      accompany DM, and DM can also promote cancer. METHODS: An analysis was conducted 
      of diabetes mellitus-related gene (DM-gene) expression levels in tumor and normal 
      tissues, clinical parameters, tumor stages, mutations, copy number variations 
      (CNVs), immune cell infiltration, survival, gene enrichment, and gene ontology 
      annotations. RESULTS: This analysis revealed six genes that appear to play key 
      roles in lung cancer survival: MTMR3 (in lung adenocarcinoma [LUAD]) and COBLL1, 
      PPARG, PPIP5K2, RREB1, and WFS1 (in lung squamous cell carcinoma [LUSC]). 
      CONCLUSION: The results suggested that clinical practitioners and researchers 
      should account for PPARG and RREB1 expression when selecting or testing 
      chemotherapy drugs.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Yang, Jincheng
AU  - Yang J
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Li, Ning
AU  - Li N
AD  - Department of Comprehensive Oncology, National Cancer Center, National Clinical 
      Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Lin, Weilong
AU  - Lin W
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Deng, Ming
AU  - Deng M
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Shi, Liming
AU  - Shi L
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - An, Yu
AU  - An Y
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Yang, Juan
AU  - Yang J
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhou, Chengcheng
AU  - Zhou C
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Tong, Qin
AU  - Tong Q
AD  - Department of Acupuncture and Moxibustion, Wuhan Xinzhou District Hospital of 
      Traditional Chinese Medicine, Wuhan, Hubei, China.
FAU - Yang, Wenjing
AU  - Yang W
AD  - Office for Cancer Diagnosis and Treatment Quality Control, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (PPAR gamma)
RN  - EC 3.1.3.48 (MTMR3 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatases, Non-Receptor)
RN  - EC 2.7.4.24 (PPIP5K2 protein, human)
RN  - EC 2.7.4.- (Phosphotransferases (Phosphate Group Acceptor))
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/genetics
MH  - DNA Copy Number Variations
MH  - PPAR gamma
MH  - *Lung Neoplasms/pathology
MH  - Prognosis
MH  - Gene Expression
MH  - Protein Tyrosine Phosphatases, Non-Receptor/genetics
MH  - Phosphotransferases (Phosphate Group Acceptor)/genetics
OTO - NOTNLM
OT  - Lung cancer
OT  - TCGA
OT  - diabetes mellitus
OT  - gene
OT  - hyperglycemia
OT  - prognosis
EDAT- 2023/05/31 06:42
MHDA- 2023/09/04 06:42
CRDT- 2023/05/31 03:42
PHST- 2022/07/07 00:00 [received]
PHST- 2023/02/06 00:00 [revised]
PHST- 2023/02/20 00:00 [accepted]
PHST- 2023/09/04 06:42 [medline]
PHST- 2023/05/31 06:42 [pubmed]
PHST- 2023/05/31 03:42 [entrez]
AID - CCDT-EPUB-132142 [pii]
AID - 10.2174/1568009623666230529154306 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2023;23(11):889-899. doi: 
      10.2174/1568009623666230529154306.